Biogen’s Anirvan Ghosh to Succeed Keith Leonard as Unity Bio CEO

Unity Biotechnology (NASDAQ: [[ticker:UBX]]), a company developing drugs to treat diseases of aging, has appointed Anirvan Ghosh to serve as its CEO. He will succeed Keith Leonard, who the company says is leaving his executive position due to personal circumstances but will remain chairman of the board of directors. Ghosh is coming to San Francisco-based Unity from Biogen (NASDAQ: [[ticker:BIIB]]), where he is senior vice president and head of research and early development. Ghosh will start at Unity on March 30. Unity’s most advanced program, osteoarthritis drug UBX101, is currently in Phase 2 testing.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan